Cargando…

Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy

BACKGROUND: This study was designed to evaluate proton magnetic resonance spectroscopy ((1)H-MRS) for monitoring the WHO grade II glioma (low-grade glioma (LGG)) treated with temozolomide (TMZ). METHODS: This prospective study included adult patients with progressive LGG that was confirmed by magnet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guillevin, R, Menuel, C, Taillibert, S, Capelle, L, Costalat, R, Abud, L, Habas, C, De Marco, G, Hoang-Xuan, K, Chiras, J, Vallée, J-N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111204/ https://www.ncbi.nlm.nih.gov/pubmed/21610707 http://dx.doi.org/10.1038/bjc.2011.174

Ejemplares similares

Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?
por: Hirst, T C, et al.
Publicado: (2013)

Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma
por: Pedretti, M, et al.
Publicado: (2010)

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
por: Hassel, J C, et al.
Publicado: (2010)

Non-thermal atmospheric plasma induces ROS-independent cell death in U373MG glioma cells and augments the cytotoxicity of temozolomide
por: Conway, Gillian E, et al.
Publicado: (2016)

Temozolomide induces senescence but not apoptosis in human melanoma cells
por: Mhaidat, N M, et al.
Publicado: (2007)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

Activity of irinotecan and temozolomide in the presence of O(6)-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models
por: Cai, W, et al.
Publicado: (2010)

Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival
por: Robinson, C G, et al.
Publicado: (2010)

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699
por: Daniel, R A, et al.
Publicado: (2010)

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53
por: Naumann, S C, et al.
Publicado: (2009)

Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy
por: Murphy, P S, et al.
Publicado: (2004)

O(6)-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts
por: Clemons, M, et al.
Publicado: (2005)

Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines
por: Mohammed, M Z, et al.
Publicado: (2011)

Protein expression in experimental malignant glioma varies over time and is altered by radiotherapy treatment
por: Wibom, C, et al.
Publicado: (2006)

The use of Raman spectroscopy to differentiate between different prostatic adenocarcinoma cell lines
por: Crow, P, et al.
Publicado: (2005)

Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling
por: Han, Sheng, et al.
Publicado: (2017)

Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium
por: Goranova, T, et al.
Publicado: (2017)

Cell migration in paediatric glioma; characterisation and potential therapeutic targeting
por: Cockle, J V, et al.
Publicado: (2015)

Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells
por: González, A, et al.
Publicado: (2007)

In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs
por: Ashley, D M, et al.
Publicado: (2008)

Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy
por: Pisanu, M E, et al.
Publicado: (2014)

Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1
por: Bertrand, Y, et al.
Publicado: (2011)

Inhibition of formyl peptide receptor in high-grade astrocytoma by CHemotaxis Inhibitory Protein of S. aureus
por: Boer, J C, et al.
Publicado: (2013)

Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids
por: Günther, W, et al.
Publicado: (2003)

TP53 regulates human AlkB homologue 2 expression in glioma resistance to Photofrin-mediated photodynamic therapy
por: Lee, S Y, et al.
Publicado: (2010)

The neuro-steroid, 3β androstene 17α diol exhibits potent cytotoxic effects on human malignant glioma and lymphoma cells through different programmed cell death pathways
por: Graf, M R, et al.
Publicado: (2007)

Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells
por: Saito, T, et al.
Publicado: (2008)

Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma
por: Arrieta, O, et al.
Publicado: (2005)

Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer
por: Harrington, Brittney S, et al.
Publicado: (2016)

Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide
por: Kanzawa, T, et al.
Publicado: (2003)

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer
por: Koti, M, et al.
Publicado: (2015)

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
por: D'Amato, V, et al.
Publicado: (2014)

Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells
por: D'Amato, C, et al.
Publicado: (2014)

Characterisations of human prostate stem cells reveal deficiency in class I UGT enzymes as a novel mechanism for castration-resistant prostate cancer
por: Williamson, S C, et al.
Publicado: (2013)

Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA
por: Henare, K, et al.
Publicado: (2012)

H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells
por: Li, C, et al.
Publicado: (2005)

Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines
por: Sawers, L, et al.
Publicado: (2014)

Prostate cancer cell malignancy via modulation of HIF-1α pathway with isoflurane and propofol alone and in combination
por: Huang, H, et al.
Publicado: (2014)

Systemically administered PEDF against primary and secondary tumours in a clinically relevant osteosarcoma model
por: Broadhead, M L, et al.
Publicado: (2011)

Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer
por: Smith, G, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_37npsvtgqcbpuioljc3f0sf3i4